Under a technology and multi-phase research agreement, CB2 will be integrating its Clinical Data Management Software (CDMS) and Electronic Data Capture (EDC) tools to establish a better understanding of VIVO’s current medical patient registry. Concurrently, the two companies will collaborate on a multi-phase research strategy that will validate the safety and efficacy of current products. The plan is ultimately expected to help inform the design of clinical trials to support the deployment of future cannabis-based medicines.
“As the industry continues to evolve, regulatory bodies are putting greater emphasis on the validation of cannabis-based treatments through clinical trial data to measure their safety and efficacy,” said Prad Sekar, CEO of CB2.
“We will work closely with the team at VIVO to design a research strategy backed by the collection of high-quality real world clinical data to support their current and future product innovations.”
“CB2’s global experience in clinical research and technology will enable VIVO to enhance our understanding of Canadian medical patients. This will facilitate our uncovering of new ways to meet the expectations of our current patients and will help inform our international growth plans,” said Barry Fishman, CEO of VIVO. “At VIVO, our purpose is to help patients achieve a positive quality of life with cannabis. We look forward to utilizing our partnership with CB2 to further bring real world evidence to the medical cannabis industry.”
VIVO is an Ontario-based cannabis company recognized for its premium products and services, to assist in the development of VIVO’s global medical product development strategy.